Jefferies analyst David Windley downgraded Icon (ICLR) to Hold from Buy with a price target of $175, down from $220. The firm now sees “too many headwinds” for Icon to continue recommending the shares. The stock is “cheap” but another guidance cut may be forthcoming, the analyst tells investors in a research note. Jefferies’ channel checks continue to show wallet share losses for Icon, which the firm believes undermine momentum from the four partnership wins since the PRA Health merger. Customer cancels are likely near $1B in 3Q and could remain high in Q4, Jefferies contends.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICLR:
- Buy Rating Affirmed for Icon Amid CEO Transition and Market Challenges
- ICON Plc and Zealand Pharma’s Petrelintide Study: A Key Update for Investors
- ICON plc’s Latest Study on Kedrion IVIG 10% for Chronic ITP: A Market Perspective
- Strategic Leadership Transition and Market Resilience Underpin Buy Rating
- ICON plc Reaffirms 2025 Financial Guidance Amid CEO Transition